REPORT FROM THE ENS 2008 – The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial demonstrated that atorvastatin 80 mg/day was effective in secondary prevention of ischemic stroke or TIA. At 4.9-year median follow-up, the absolute risk reduction for ischemic stroke with atorvastatin versus placebo was 2.2% (adjusted HR 0.78), although more hemorrhagic strokes occurred in the active treatment group (55 vs. 33; adjusted HR 1.66) (Amarenco et al. N Engl J Med 2006;355:549-59).
Read More
Neurology
Beta-interferons in CIS: Cochrane meta-analysis
September 23, 2008REPORT FROM THE ENS 2008 – Beta-interferons are effective in preventing the conversion of clinically isolated syndrome (CIS) suggestive of MS to clinically definite MS, according to the results of a Cochrane meta-analysis (Clerico et al. Abstract 0160. J Neurol 2008;255(suppl 2): 37; published as Clerico et al. Cochrane Database Syst Rev 2008;April 16(2):CD005278).
Read More
Functional neuroimaging of vascular parkinsonism
September 23, 2008REPORT FROM THE ENS 2008 – Functional imaging is potentially useful in the differential diagnosis of vascular parkinsonism but larger studies are needed to identify the optimal methodology, according to a literature review presented at the ENS (Kalra et. al. Abstract P798. J Neurol 2008;255(suppl 2): 198).
Lumbar puncture: what is its effectiveness in the ER?
September 23, 2008REPORT FROM THE ENS 2008 – Lumbar punctures may be performed in the emergency medical department setting to investigate CNS infection, subarachnoid hemorrhage or polyradiculoneuropathy.
Read More
Glatiramer acetate in CIS
September 9, 2008
Leave a reply
REPORT FROM THE ENS 2008 – Glatiramer acetate significantly delays progression to clinically-definite MS (CDMS) in patients with clinically-isolated syndrome (CIS), according to data from the PRECISE trial (Comi et al. Abstract 059. J Neurol 2008;255(suppl 2): 10). The results were initially reported at the American Academy of Neurology 60th annual meeting, April 16, 2008.